Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
| Conditions: | Mesothelioma |
| Start Date: | April 1, 2008 |
| Phase: | Phase I|Phase II |
| Status: | Withdrawn |
| NCT ID: | NCT00668499 |
| Study Type: | Interventional |
| Intervention: | Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin |
| Study Design: | Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | USC/Norris Comprehensive Cancer Center|Sponsor Name Pending |
| Ages: | Adult|Senior |
| Enrollment: | 71 |
| Funded By: | Other|Industry |
| First Received: | April 25, 2008 |
| End Date: | April 1, 2011 |
| Last Updated: | January 8, 2009 |
| Last Verified: | January 1, 2009 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
